NCT00277602CompletedPhase 3
A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 537
- Primary Endpoint
- UHDRS-motor score, TFC
Study Overview
Brief Summary
Primary objective:
- The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating Scale (UHDRS) as well as (3) the increase of a combined score of these.
Secondary objectives:
Secondary objectives are to assess
- changes in the other UHDRS subscales
- the number of patients who need antichoreic treatment and the time until this treatment has to be initiated
- the safety/tolerability of riluzole in Huntington patients
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 25 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical diagnosis of Huntington's disease and CAG repeat length of 36 or more
- •UHDRS Motor score of at least 5 points
- •UHDRS TFC score of at least 8 points, i.e. patients must be independently ambulatory and must not require nursing care
- •Females require a negative blood pregnancy test at inclusion
Exclusion Criteria
- •Any forms of chorea other than Huntington's disease
- •Patients on antichoreic treatment within one month prior to entry or foreseen to require such treatment within the first 3 months after randomization (antichoreic medication is prohibited during entire study)
- •Other unacceptable prior/concomitant medications
- •Uncontrolled major psychiatric disorders, in particular uncontrolled major depression (DSM IV definition)
- •Drug or alcohol dependence and/or abuse (DSM IV definition) within the past 6 months
- •Any other concomitant disease with a reasonable possibility to interfere with the study
- •Females who are breast-feeding, not sterilized, at least one year postmenopausal or don't use an adequate contraceptive method for at least one month prior to and during study participation
- •Participation in another clinical study with any investigational drug within 30 days prior to study screening
- •Prior exposure to riluzole
- •ALT and/or AST and/or Total Bilirubin levels greater than 1.5 times the upper limits of normal range, or hepatic disease other than Gilbert's disease
- •Creatinine serum concentrations above 200 µmol/l (resp. 2,3 mg/dl) or hematology parameters as follows: Hemoglobin smaller 11 g/dl for males resp. smaller 10 g/dl for females, or White Blood Cell smaller 3,5 x 10000000000/l
Outcomes
Primary Outcomes
UHDRS-motor score, TFC
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Suspended
Phase 2
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.Oxaliplatin-induced Peripheral NeuropathyNCT03722680UNICANCER80
Terminated
Phase 3
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Progressive Supranuclear PalsyMultiple System AtrophyNCT00211224King's College London800
Terminated
Phase 2
Riluzole in Spinal Cord Injury StudySpinal Cord InjuryNCT01597518AOSpine North America Research Network193
Active, not recruiting
Phase 1
_Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4)EUCTR2017-002320-25-FRICANCER210
Completed
Early Phase 1
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum DisordersAutism Spectrum DisordersNCT02081027Children's Hospital Medical Center, Cincinnati8